Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

4,072 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase Ib open-label, multicenter study of pixatimod, an activator of TLR9, in combination with nivolumab in subjects with microsatellite-stable metastatic colorectal cancer, metastatic pancreatic ductal adenocarcinoma and other solid tumors.
Lemech C, Dredge K, Bampton D, Hammond E, Clouston A, Waterhouse NJ, Stanley AC, Leveque-El Mouttie L, Chojnowski GM, Haydon A, Pavlakis N, Burge M, Brown MP, Goldstein D. Lemech C, et al. Among authors: goldstein d. J Immunother Cancer. 2023 Jan;11(1):e006136. doi: 10.1136/jitc-2022-006136. J Immunother Cancer. 2023. PMID: 36634920 Free PMC article. Clinical Trial.
The AGITG GAP Study: A Phase II Study of Perioperative Gemcitabine and Nab-Paclitaxel for Resectable Pancreas Cancer.
Barbour AP, Samra JS, Haghighi KS, Donoghoe MW, Burge M, Harris MT, Chua YJ, Mitchell J, O'Rourke N, Chan H, Gebski VJ, Gananadha S, Croagh DG, Kench JG, Goldstein D; Australasian Gastro-Intestinal Trials Group (AGITG) GAP investigators. Barbour AP, et al. Among authors: goldstein d. Ann Surg Oncol. 2020 Jul;27(7):2506-2515. doi: 10.1245/s10434-020-08205-2. Epub 2020 Jan 29. Ann Surg Oncol. 2020. PMID: 31997125 Clinical Trial.
C-reactive protein is a prognostic biomarker in pancreatic ductal adenocarcinoma patients.
Bonazzi VF, Aoude LG, Brosda S, Bradford JJ, Lonie JM, Loffler KA, Gartside MG, Patel K, Mukhopadhyay P, Keane C, Gebski V, Kench JG, Goldstein D, Waddell N, Barbour AP; Australasian Gastro-Intestinal Trials Group (AGITG) GAP investigators. Bonazzi VF, et al. Among authors: goldstein d. Asia Pac J Clin Oncol. 2023 Jul 6. doi: 10.1111/ajco.13993. Online ahead of print. Asia Pac J Clin Oncol. 2023. PMID: 37415393
Metastatic phenotype and immunosuppressive tumour microenvironment in pancreatic ductal adenocarcinoma: Key role of the urokinase plasminogen activator (PLAU).
Hosen SMZ, Uddin MN, Xu Z, Buckley BJ, Perera C, Pang TCY, Mekapogu AR, Moni MA, Notta F, Gallinger S, Pirola R, Wilson J, Ranson M, Goldstein D, Apte M. Hosen SMZ, et al. Among authors: goldstein d. Front Immunol. 2022 Dec 14;13:1060957. doi: 10.3389/fimmu.2022.1060957. eCollection 2022. Front Immunol. 2022. PMID: 36591282 Free PMC article.
HGF/c-Met pathway inhibition combined with chemotherapy increases cytotoxic T-cell infiltration and inhibits pancreatic tumour growth and metastasis.
Mekapogu AR, Xu Z, Pothula S, Perera C, Pang T, Hosen SMZ, Damalanka V, Janetka J, Goldstein D, Pirola R, Wilson J, Apte M. Mekapogu AR, et al. Among authors: goldstein d. Cancer Lett. 2023 Aug 1;568:216286. doi: 10.1016/j.canlet.2023.216286. Epub 2023 Jun 22. Cancer Lett. 2023. PMID: 37354984 Free article.
4,072 results